Anti-Müllerian hormone – a predictor of ovarian reserve
Abstract
Background: Since women nowadays experience late decision for the delivery of the first child the question of screening strategies for ovarian reserve determination and fertility potential seems to be crucial. As the most reliable marker of ovarian function FSH determination has been used, but the method is limited with fluctuation from physiologic to pathologic levels up to some years before exhaustion of ovarian reserve. In the past ten years determination of anti-Müllerian hormone (AMH) concentration in serum has become most relevant. AMH is produced and secreted by granulosa cells and regulates the development of primary follicles with inhibitory action on FSH secretion. AMH does not only predict the pool of small antral follicles but can also be a predictor of oocyte quality. In men AMH determination has been useful in diagnostic procedures for intersex conditions with abnormal testicular differentiation, while in women AMH tends to be the most reliable marker for small antral follicle pool in premature ovarian failure and the marker of increased reserve of small antral follicles in women with polycystic ovaries. Conclusion: Recent scientific and clinical data suggest that AMH determination will be used as the most reliable marker of ovarian follicular status.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
